In the first-line setting, pembrolizumab has become the standard of care for metastatic NSCLC patients with tumor expression of PD-L1 over 50%, a condition that may occur in approximately 30% of NSCLC cases (170). Here, CD274 is linked to non-small cell lung carcinoma.